Recent advances in the biology of central nervous system tumors

Current Opinion in Neurology

Volumn 10, Issue 6, 1997, Pages 445-451

  Ashley, David M ^a   Bigner, Darell D ^b,c  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; APOPTOSIS; BRAIN TUMOR; CELL CYCLE; CENTRAL NERVOUS SYSTEM TUMOR; HUMAN; MOLECULAR CLONING; PATIENT CARE; REVIEW; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 0030727045     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199712000-00002     Document Type: Review

References (84)

1. Dirks PB, Rutka JR: Curent concepts in neuro-oncology: the cell cycle - a review. Neurosurgery 1997, 40:1000-1013. An up to date review of cell cycle aberrations in brain tumors.
2. Dirks PB, Hubbard SL, Murakami M, Rutka JT: Cyclin and cyclin-dependent kinase expression in human astrocytoma cell lines. J Neuropathol Exp Neurol 1997, 53:291-300.
3. Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Willson JK, Kinzler KW, Vogelstein B: Deletion of p16 and p15 genes in brain tumors. Cancer Res 1994, 54:6353-6358.
4. Kyritsis AP, Zhang B, Zhang W, Xiao M, Takeshima H, Bondy ML, Cunningham JE, Levin VA, Bruner J: Mutations of the p16 gene in gliomas. Oncogene 1996, 12:63-67.
5. Moulton T, Samara G, Chung WY, Yuan L, Desai R, Sisti M, Bruce J, Tycko B: MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Am J Pathol 1995, 146:613-619.
6. Nishikawa R, Furnari FB, Lin H, Arap W, Berger MS, Cavenee WK, Su Huang HJ: Loss of P161NK4 expression is frequent in high grade gliomas. Cancer Res 1995, 55:1941-1945.
7. Ono Y, Tamiya Y, Ichikawa T, Kunishio K, Matsumoto K, Furuta T, Ohmoto T Ueki K, Louis DN: Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices. J Neuropathol Exp Neuron 1996, 55:1026-1031.
8. Walker DG, Duan W, Popovic EA, Kaye AH, Tomlinson FH, Lavin M: Homozygous deletions of the multiple tumor supressor gene 1 in the progression of human astrocytomas. Cancer Res 1995, 55:20-23.
9. Woloschak M, Yu A, Xiao J, Post KD: Frequent loss of the P161NK4a gene product in human pituitary tumors. Cancer Res 1996, 56:2493-2496.
10. Ono Y, Ueki K, Joseph JT, Louis DN: Homozygous deletions of the CDKN2/p16 gene in dural hemangiopericytomas. Acta Neuropathol (Berl) 1996, 91:221-225.
11. Petronio J, He J, Fults D, Pedone C, James CD, Allen JR: Common alternative gene alterations in adult malignant astrocytomas, but not in childhood primitive neuroectodermal tumors - P16ink4 homozygous deletions and Cdk4 gene amplfications. J Neurosurg 1996,84:1020-1023.
12. Sonoda Y, Yoshimoto T, Sekiya T: Homozygous deletion of the MTS1/P16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma. Oncogene 1995, 11:2145-2149.
13. He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day RSR, James CD: CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 1994, 54:5804-5807.
14. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN: CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996, 56:150-153.
15. Kyritsis AP, Saya H: Epidemiology, cytogenetics, and molecular biology of brain tumors. Curr Opin Oncol 1993, 5:474-480.
16. Mikkelsen T: Recent advances in brain tumor molecular biology. Curr Opin Oncol 1994, 6:229-234.
17. Raffel C: Molecular biology of pediatric gliomas. J Neurooncol 1996, 28:121-128.
18. Velculescu VE, EI-Deiry WS: Biological and clinical importance of the p53 tumor suppresor gene. Clin Chem 1996, 42:858-868.
19. Chen J, Willingham T, Shuford M, Bruce D, Rushing E, Smith Y, Nisen PD: Effects of ectopic overexpression of P21waf1/Cip1 on aneuploidy and the malignant phenotype of human brain tumor cells. Oncogene 1996, 13:1395-1403.
20. Batra SK, Rasheed BK, Bigner SH, Bigner DD: Oncogenes and antioncogenes in human central nervous system tumors. Lab Invest 1994, 71:621-637.
21. Batra SK, Castelino-Prabhu S, Wikstrand CJ, Xiaopei Z, Humphrey PA, Frtedman HS, Bigner DD: Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvlll gene. Cell Growth Diff 1995, 6:1251-1259.
22. Yamazaki H, Ohba Y, Tamaoki N, Shibuya M: A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors. Jpn J Can Res 1990, 81:773-779.
23. Nishikawa R, Ji XD, Harmon RC, LazarCS, Gill GN, Cavenee WK, Huang HJ: A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 1994, 91:7727-7731.
24. Huang HJS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD, Huang CM, Gill GN, Wiley HS, Cavenee WK: The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 1997, 272:2927-2935.
25. Garcia R, Bueno A, Castanon S, Ruiz-Barnes P, Maria de Campos J, Kusak E, Fortes JR, Ortiz F, Sarasa JL: Study of the DNA content by flow cytometry and proliferation in 281 brain tumors. Oncology 1997, 54:112-117.
26. Patsouris E, Davaki P, Kapranos N, Davaris P, Papageorgiou K: A study of apoptosis in brain tumors by in situ end-labeling method. Clin Neuropathol 1996, 15:337-341.
27. Nakagawa S, Shiraishi T, Kihara S, Tabuchi K: Detection of DNA strand breaks associated with apoptosis in human brain tumors. Virchows Arch 1995, 427:175-179.
28. Uren AG, Vaux DL: Molecular and clinical aspects of apoptosis. Pharmacol Ther 1996, 72:37-50.
29. Barker FGN, Israel MA: The molecular biology of brain tumors. Neurol Clin 1995, 13:701-721.
30. Pollack IF, Hamilton RL, Finkelstein SD, Campbell JW, Martinez AJ, Sherwin RN, Bozik ME, Gollin SM: The relationship between Tp53 mutations and overexpression of P53 and prognosis in malignant gllomas of childhood. Cancer Res 1997, 57:304-309.
31. Gomez-Manzano C, Fueyo J, Kyritsis AP, Steck PA, Roth JA, McDonnell TJ, Steck KD, Levin VA, Yung WK: Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 1996, 56:694-699.
32. Kondo S, Barna BP, Kondo Y, Tanaka Y, Casey G, Liu J, Morimura T, Kaakaji R, Peterson JW, Werbel B, Barnett GH: WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Oncogens 1996, 13:1279-1285.
33. Beutler B, van Huffel C: Unraveling function in the TNF ligand and receptor families [Comment]. Science 1994, 264:667-668.
34. Berke G: Killing mechanisms of cytotoxic lymphocytes. Curr Opin Hematol 1997, 4:32-40.
35. Ashley DM, Kong FM, Bigner DD, Hale LP: Endogenous expression of transforming growth factor β1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high grade gliana model. Cancer Res 1997 (in press).
36. Ashley DM, Sampson JA, Archer GE, Hale LP, Bigner DD: Local production of TGF β1 inhibits cerebral edema, enhances TNF-α induced apoptosis and improves survival in a murine glioma model. Cancer Res 1997 (in press).
37. Weller M, Malipiero U, Rensing-Ehl A, Barr PJ, Fontana A: Fas/APO-1 gene transfer for human malignant glioma. Cancer Res 1995, 55:2936-2944.
38. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A: Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest 1994, 94:954-964.
39. Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A: Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 1995, 95:2633-2643.
40. Das H, Reddy EP, Chatterjee D, Andrews DW: Identification of a novel Bcl-2 related gene, Brag-1, in human glioma. Oncogene 1996, 12:947-951. The identification of a novel brain tumor associated apoptosis associated gene.
41. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R et al.: Pten, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947. One of two independent groups describe the identification and partial characterization of this gene mapped to the 10q23 region deleted in human glioblastoma.
42. Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T et al.: Identification of a candidate tumour suppressor gene, Mmac1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Natural Genet 1997, 15:356-362. See [41].
43. Fontana A, Constam DB, Frei K, Malipiero U, Pfister HW: Modulation of the immune response by transforming growth factor beta [Review]. Int Arch Allergy Immunol 1992, 99:1-7.
44. Johnson MD, Jennings MT, Gold LI, Moses HL: Transforming growth factor-beta in neural embryogenesis and neoplasia. Hum Pathol 1993, 241:457-462.
45. Massague J: The TGF-beta family of growth and differentiation factors. Cell 1987, 49:437-438.
46. Cheifetz S, Weatherbee JA, Tsang ML, Anderson JK, Mole JE, Lucas R, Massague J: The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors. Cell 1987, 48:409-115.
47. Massague J, Andres J, Attisano L, Cheifetz S, Lopez-Casillas F, Ohtsuki M, Wrana JL: TGF-beta receptors. Mol Reprod Dev 1992, 32:99-104.
48. Moses HL, Pietenpol JA, Munger K, Murphy CS, Yang EY: TGF beta regulation of epithelial cell proliferation: role of tumor suppressor genes. Princess Takamatsu Symp 1991, 22:183-195.
49. Moses HL, Yang EY, Pietenpol JA: TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 1990, 63:245-247.
50. de Martin R, Haendler B, Hofer-Warbinek R, Gaugitsch H, Wrann M, Schlusener H, Seifert JM, Bodmer S, Fontana A, Hofer E: Complementary DMA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family. Embo J 1987, 6:3673-3677.
51. Gold LI, Korc M: Expression of transforming growth factor-β1,2 and 3 mRNA and protein in human cancer. Dig Surg 1994, 11:150-156
52. Tada M, de Tribolet N: Recent advances in immunobiology of brain tumors [Review]. J Neurooncol 1993, 17:261-271.
53. Kurpad SN, Wikstrand CJ, Bigner DD: Immunobiology of malignant astrocytomas [Review]. Semin Oncol 1994, 21:149-161.
54. Jaeckle KA: Immunotherapy of malignant gliomas [Review]. Semin Oncol 1994, 21:249-259.
55. Fontana A, Bodmer S, Frei K, Malipiero U, Siepl C: Expression of TGF-beta 2 in human glioblastoma: a role in resistance to immune rejection? [Review]. Ciba Found Symp 1991, 157:232-238.
56. Weller M, Fontana A: The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain [Review]. Brain Res Brain Res Rev 1995, 21:128-151.
57. Tada M, de Tribolet N: Recent advances in immunobiology of brain tumors. J Neurooncol 1993, 17:261- 271.
58. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE: Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 1996, 93:2909-2914.
59. Jachimczak P, Bogdahn U, Schneider J, Behl C, Meixensberger J, Apfel R, Dorries R, Schlingensiepen KH, Brysch W: The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligo-deoxynucleotides in reversing cellular immunosupression in malignant glioma. J Neurosurg 1993, 78:944-951.
60. Jachimczak P, Schwulera U, Bogdahn U: In vitro studies of cytokine-mediated interactions between malignant glioma and autologous peripheral blood mononuclear cells. J Neurosurg 1994, 81:579-586.
61. Jachimczak P, Fabel-Schulte K, Hessdorfer B, Brysch W, Schlingensiepen KH, Blesch A, Bogdahn U: Transforming growth factor-beta-mediated regulation of human peripheral blood mononuclear cell proliferation as detected with phosphorothioate antisense oligodeoxynucleotides. Cell Immunol 1995, 165:125-133.
62. Jachimczak P, Hessdorfer B, Fabel-Schulte K, Wismeth C, Brysch W, Schlingensiepen KH, Bauer A, Blesch A, Bogdahn U: Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides. Int J Cancer 1996, 65:332-337.
63. Guerin C, Laterra J: Regulation of angiogenesis in malignant gliomas. Exs 1997, 79:47-64.
64. Plate KH, Breier G, Millauer B, Ullrich A, Risau W: Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 1993, 53:5822-5827.
65. Cheng SY, Huang HJS, Nagane M, Ji XD, Wang DG, Shih CCY, Arap W, Huang CM, Cavenee WK: Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Nat Acad Sci USA 1996, 93:8502-8507. The authors examine the effect of modulation of the VEGF gene on brain tumor growth.
66. Heiss JD, Papavassiliou E, Merrill MJ, Nieman L, Knightly JJ, Walbridge S, Edwards NA, Oldfield EH: Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest 1996, 98:1400-1408. The authors investigate some of the mechanisms underlying the pathogenesis of tumor related cerebral edema.
67. Ryuto M, Ono M, Izumi H, Yoshida S, Weich HA, Kohno K, Kuwano M: Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem 1996, 271:28220-28228.
68. Saukkonen K, Sande S, Cioffe C, Wolpe S, Sherry B, Cerami A, Tuomanen E: The role of cytokines in the generation of inflammation and tissue damage in experimental gram-positive meningitis. J Exp Med 1990, 171:439-448.
69. Frei K, Piani D, Pfister HW, Fontana A: Immune-mediated injury in bacterial meningitis. Int Rev Exp Pathol 1993, 34:183-192.
70. Renno T, Krakowski M, Piccirillo C, Lin JY, Owens T: TNF-alpha expression by resident microglia and infiltrating leukocytes in the central nervous system of mice with experimental allergic encephalomyelitis. Regulation by Th1 cytokines. J Immunol 1995, 154:944-953.
71. Pfister HW, Frei K, Ottnad B, Koedel U, Tomasz A, Fontana A: Transforming growth factor beta 2 inhibits cerebrovascular changes and brain edema formation in the tumor necrosis factor alpha-independent early phase of experimental pneumococcal meningitis. J Exp Med 1992, 176:265-268.
72. Arap W, Nishikawa R, Furnari FB, Cavenee WK, Huang HJ: Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res 1995, 55:1351-1354.
73. Kamada H, Murakami H, Satone A, Ikeda M, Yamaguchi H, Matsumoto A, Ide W, Hashimoto I, Ukita H: [7Up-regulation of NGF, trkA, Fas, down-regulation of bcl-2. and induction of apoptosis by propentofylline in human glioma cell lines]. No To Shinkei 1996, 48:1022-1028.
74. Mizuno M, Yoshida J: Tumor necrosis factor-alpha gene transfer augments anti-Fas antibody-mediated apoptosis in human glioma cells. Jpn Journal of Cancer Research 1996, 87:543-547.
75. Muragaki Y, Chou TT, Kaplan DR, Trojanowski JQ, Lee VMY: Nerve growth factor induces apoptosis in human medulloblastoma cell lines that express TrkA receptors. J Neurosci 1997,17:530-542.
76. Yu JS, Sena-Esteves M, Paulus W, Breakefield XO, Reeves SA: Retroviral delivery and tetracycline-dependent expression of IL-1 beta-converting enzyme (ICE) in a rat glioma model provides controlled induction of apoptotic death in tumor cells. Cancer Res 1996, 56:5423-5427.
77. Roth W, Fontana A, Trepel M, Reed JC, Dichgans J, Weller M: Immunochemotherapy of malignant glioma - synergistic activity of Cd95 ligand and chemotherapeutics. Cancer Immunol Immunother 1997, 44:55-63.
78. Phillips PC, Levow C, Catterall M, Colvin OM, Pastan I, Brem H: Transforming growth factor-alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice. Cancer Res 1994, 54:1008-1015.
79. Ashley DM, Batra SK, Bigner DD: Monoclonal antibodies to growth factors and growth factor receptors: their diagnostic and therapeutic potential in brain tumors. J Neuro-Oncol 1997 (in press).
80. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ et al.: Monoclonal antibodies against EGFRvlll are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1994, 55:3140-3148.
81. Lorimer IAJ, Wikstrand CJ, Batra SK, Bigner DD, Pastan I: Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. Clin Cancer Res 1995, 18:859-864.
82. Lorimer IAJ, Kepplerhafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I: Recombinant immunotoxins specific for a mutant epidermal growth factor receptor - targeting with a single chain antibody variable domain isolated by phage display. Proc Nat Acad Sci USA 1996, 93:14815-14820.
83. Olopade OI, Jenkins RB, Ransom DT, Malik K, Pomykala H, Nobori T, Cowan JM, Rowley JD, Diaz MO: Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas. Cancer Res 1992, 52:2523-2529.
84. Wu DJ, Reynolds L, Carson DA, Nobori T: Molecular genetic analysis of chromosome 9p in methylthioadenosine phosphorylase deficient glioma cell lines. Adv Exp Med Biol 1991, 309:208-211.